JP2005516925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516925A5 JP2005516925A5 JP2003552287A JP2003552287A JP2005516925A5 JP 2005516925 A5 JP2005516925 A5 JP 2005516925A5 JP 2003552287 A JP2003552287 A JP 2003552287A JP 2003552287 A JP2003552287 A JP 2003552287A JP 2005516925 A5 JP2005516925 A5 JP 2005516925A5
- Authority
- JP
- Japan
- Prior art keywords
- darifenacin
- overactive bladder
- urgency
- pharmaceutically acceptable
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 16
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 16
- 208000020629 overactive bladder Diseases 0.000 claims description 16
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 11
- 229960002677 darifenacin Drugs 0.000 claims description 10
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010027566 Micturition urgency Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129962.7A GB0129962D0 (en) | 2001-12-14 | 2001-12-14 | Method of treatment |
| PCT/IB2002/000664 WO2003051354A1 (en) | 2001-12-14 | 2002-03-05 | Method of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009250519A Division JP2010024244A (ja) | 2001-12-14 | 2009-10-30 | 処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516925A JP2005516925A (ja) | 2005-06-09 |
| JP2005516925A5 true JP2005516925A5 (enExample) | 2010-01-21 |
Family
ID=9927643
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552287A Withdrawn JP2005516925A (ja) | 2001-12-14 | 2002-03-05 | 処置方法 |
| JP2009250519A Withdrawn JP2010024244A (ja) | 2001-12-14 | 2009-10-30 | 処置方法 |
| JP2013145736A Pending JP2013199506A (ja) | 2001-12-14 | 2013-07-11 | 処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009250519A Withdrawn JP2010024244A (ja) | 2001-12-14 | 2009-10-30 | 処置方法 |
| JP2013145736A Pending JP2013199506A (ja) | 2001-12-14 | 2013-07-11 | 処置方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20030130338A1 (enExample) |
| EP (1) | EP1458376B1 (enExample) |
| JP (3) | JP2005516925A (enExample) |
| KR (1) | KR100889086B1 (enExample) |
| CN (1) | CN100488505C (enExample) |
| AT (1) | ATE341323T1 (enExample) |
| AU (1) | AU2002236141B2 (enExample) |
| BR (1) | BR0214925A (enExample) |
| CA (1) | CA2469702C (enExample) |
| CY (1) | CY1105814T1 (enExample) |
| CZ (1) | CZ301283B6 (enExample) |
| DE (1) | DE60215219T2 (enExample) |
| DK (1) | DK1458376T3 (enExample) |
| ES (1) | ES2276910T3 (enExample) |
| GB (1) | GB0129962D0 (enExample) |
| HU (1) | HU229908B1 (enExample) |
| IL (2) | IL162391A0 (enExample) |
| MX (1) | MXPA04005760A (enExample) |
| NO (1) | NO20042586L (enExample) |
| NZ (1) | NZ533421A (enExample) |
| PL (1) | PL206034B1 (enExample) |
| PT (1) | PT1458376E (enExample) |
| RU (1) | RU2321398C2 (enExample) |
| SI (1) | SI1458376T1 (enExample) |
| SK (1) | SK287510B6 (enExample) |
| WO (1) | WO2003051354A1 (enExample) |
| ZA (1) | ZA200404289B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090062326A1 (en) * | 2006-03-17 | 2009-03-05 | Spindel Eliot R | M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors |
| CN101084891A (zh) * | 2007-06-29 | 2007-12-12 | 北京本草天源药物研究院 | 一种用于口服的达非那新或其药用盐的药物制剂 |
| CZ300895B6 (cs) * | 2008-01-28 | 2009-09-02 | Zentiva, A. S. | Zpusob prípravy Darifenacinu |
| WO2010090172A1 (ja) * | 2009-02-04 | 2010-08-12 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| CN102048706B (zh) * | 2011-01-12 | 2012-02-22 | 山东创新药物研发有限公司 | 一种氢溴酸达非那新缓释片及制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906166D0 (en) * | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
-
2001
- 2001-12-14 GB GBGB0129962.7A patent/GB0129962D0/en not_active Ceased
-
2002
- 2002-03-05 JP JP2003552287A patent/JP2005516925A/ja not_active Withdrawn
- 2002-03-05 CZ CZ20040719A patent/CZ301283B6/cs not_active IP Right Cessation
- 2002-03-05 ES ES02702623T patent/ES2276910T3/es not_active Expired - Lifetime
- 2002-03-05 HU HU0402625A patent/HU229908B1/hu not_active IP Right Cessation
- 2002-03-05 BR BR0214925-7A patent/BR0214925A/pt active Search and Examination
- 2002-03-05 CN CNB028249364A patent/CN100488505C/zh not_active Expired - Lifetime
- 2002-03-05 DK DK02702623T patent/DK1458376T3/da active
- 2002-03-05 IL IL16239102A patent/IL162391A0/xx unknown
- 2002-03-05 DE DE60215219T patent/DE60215219T2/de not_active Expired - Lifetime
- 2002-03-05 EP EP02702623A patent/EP1458376B1/en not_active Expired - Lifetime
- 2002-03-05 MX MXPA04005760A patent/MXPA04005760A/es active IP Right Grant
- 2002-03-05 AT AT02702623T patent/ATE341323T1/de active
- 2002-03-05 RU RU2004121780/15A patent/RU2321398C2/ru active
- 2002-03-05 AU AU2002236141A patent/AU2002236141B2/en not_active Expired
- 2002-03-05 SK SK250-2004A patent/SK287510B6/sk not_active IP Right Cessation
- 2002-03-05 WO PCT/IB2002/000664 patent/WO2003051354A1/en not_active Ceased
- 2002-03-05 NZ NZ533421A patent/NZ533421A/en not_active IP Right Cessation
- 2002-03-05 CA CA2469702A patent/CA2469702C/en not_active Expired - Lifetime
- 2002-03-05 PL PL369426A patent/PL206034B1/pl unknown
- 2002-03-05 SI SI200230464T patent/SI1458376T1/sl unknown
- 2002-03-05 PT PT02702623T patent/PT1458376E/pt unknown
- 2002-03-05 KR KR1020047009000A patent/KR100889086B1/ko not_active Expired - Lifetime
- 2002-09-26 US US10/256,420 patent/US20030130338A1/en not_active Abandoned
-
2004
- 2004-06-01 ZA ZA2004/04289A patent/ZA200404289B/en unknown
- 2004-06-07 IL IL162391A patent/IL162391A/en active IP Right Grant
- 2004-06-18 NO NO20042586A patent/NO20042586L/no not_active Application Discontinuation
-
2006
- 2006-11-30 CY CY20061101729T patent/CY1105814T1/el unknown
-
2007
- 2007-07-19 US US11/880,006 patent/US20070264333A1/en not_active Abandoned
-
2009
- 2009-03-04 US US12/397,433 patent/US8748476B2/en not_active Expired - Lifetime
- 2009-10-30 JP JP2009250519A patent/JP2010024244A/ja not_active Withdrawn
-
2013
- 2013-07-11 JP JP2013145736A patent/JP2013199506A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4359412B2 (ja) | ニメスリドを含む制御放出組成物 | |
| CN1235578C (zh) | 富马酸微型片剂 | |
| US20240325313A1 (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
| KR20140015140A (ko) | 리팍시민의 고형 분산물 | |
| JP2001172181A (ja) | 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠 | |
| JP2003535110A5 (enExample) | ||
| WO2011127829A1 (zh) | 纳米碳颗粒作为治疗痔疮的外用药物的应用 | |
| JP2004505036A5 (enExample) | ||
| HUT76542A (en) | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy | |
| TWI490209B (zh) | ４－甲基吡唑調配物 | |
| JP2013199506A (ja) | 処置方法 | |
| JP2005516925A5 (enExample) | ||
| JPH05246845A (ja) | イブプロフェン含有解熱鎮痛剤 | |
| Armstrong et al. | Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder | |
| ES2360461T3 (es) | Agente preventivo o terapéutico para enfermedad inflamatoria del intestino. | |
| WO2023155938A2 (zh) | 脆弱拟杆菌的荚膜多糖提取物在制备防治阿尔茨海默病的药物中的应用 | |
| JPH0324014A (ja) | 良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途 | |
| US20200297659A1 (en) | Methods of diagnosis and treatment involving nitrite | |
| KR102239649B1 (ko) | 염증성 장 질환의 치료를 위한 티아졸로 피리미딘온의 용도 | |
| JP2002507566A5 (enExample) | ||
| CN1165306C (zh) | 抗感冒的复方药物组合物 | |
| WO2016047662A1 (ja) | 脳卒中の治療剤 | |
| CN112263581A (zh) | 一种治疗pe和ed的双层片复方制剂及其制备方法 | |
| CN106038574A (zh) | 用于hrt的低剂量的固体口服剂型 | |
| HU214601B (hu) | Eljárás sabeluzolt tartalmazó gyulladásgátló és gasztroprotektív hatású készítmények előállítására |